Clinical Trial Update: Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial updating long-term safety of SPD489 added to stable antipsychotics in adults with schizophrenia and negative symptoms; study terminated with poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• SPD489

Snippet

Sponsor: Shire | Conditions: Schizophrenia | Phase 3 | Status: TERMINATED | Results posted: 2014-05-29